Guidelines for Abstract Submission: Posters are to present new research and case findings. There shall be only one presenter per virtual poster (see Guidelines below for permitted substitutions). An abstract relating to the poster content shall be submitted by the stated deadline. After review, the submitting author will be notified if accepted for in-person poster presentation and given information regarding the specifics of presenting. In addition to submitting the overall poster abstract (maximum of 300 words), which shall be a concise description of results, findings, and conclusions, the presenter shall submit (i) the poster title (ii) presenter information (name and credentials, affiliation, e-mail, and telephone), (iii) list all co-authors, separated only by commas (name and credentials, academic affiliation not required unless changed to be the substitute presenter.) All presenters must be available to present at the meeting and must register for the meeting prior to the date of their presentation. Only one submission per person. Guidelines for Poster Session: There may only be one presenter for each poster and the presenter must be included among the authors listed on the abstract submission. If the researcher or named first author who submitted the poster cannot attend the meeting and wishes to have a co-author substitute, please notify the IPS office ([email protected]). The substitute presenter must provide contact information and agree to the IPS Poster Guidelines, as well as be a member of IPS, in order to be included as the presenter at the meeting. The substitute presenter will be considered the named first author for purposes of peer judging and recognition. Posters must report only findings of the research/case report. No advertising or product identification by brand name is allowed. If any or all of the work in this poster was prepared with commercial support, a statement “Supported by funding from [name of company]” must be noted in the lower left corner of the poster in clearly identifiable font, with no bold, italics, special colors, or other enhancement of the company name, product, or any other portions of the statement. Generic names of drugs should be used throughout the poster; if brand names must be used, they must be used for all products referenced. Information regarding unapproved uses of approved products or investigational uses of unapproved products must be clearly presented with the following statement included on the poster: “The following information concerns a use that has not been approved by the U.S. Food and Drug Administration.” The presenter must wear only their IPS meeting badge and not badges or insignia of companies. No company or product identification may be included on badges or otherwise worn by the presenter. If providing handouts, the handouts must be limited to one page. The handouts must include the disclosure information on the funding of the research: “The research reported here was supported by [name of company].” Generic names of drugs should be used throughout in the handout. Any information regarding unapproved uses of approved products or investigational uses of unapproved products must include the following statement: “The following information concerns a use that has not been approved by the U.S. Food and Drug Administration.”